Adoptive T-cell therapies using tumour-specific T-cell receptors (TCRs) are limited by competition with endogenous receptors, impairing efficacy and posing risks of off-target autoreactivity. Here we present a CRISPR-based platform that selectively eliminates both endogenous TCR-α and -β chains without affecting transgenic TCRs, irrespective of codon optimization. This approach achieves >90% deletion efficiency in Jurkat and primary human T cells, enhancing expression and functional potency of transgenic receptors. Using an HLA-A*02:01-restricted DMF5 TCR, we show that dual TCR ablation boosts antigen-specific activation and cytotoxicity in vitro and enhances tumor clearance in vivo in human immune system (HIS) mice and prevents graft-versus-host disease (GVHD). Targeted locus amplification showed that CRISPR-induced double-strand breaks did not alter lentiviral integration profiles, supporting genomic safety. Extending this approach to four insulin-reactive TCRs demonstrated that endogenous receptor removal increased transduction efficiency and functional activity, with one (1E6) showing selective activation and infiltration of islet grafts (SC-islets) in vivo. This study establishes a universal, safe, and scalable genome-editing platform for generating functionally precise human T cells. By integrating cancer immunotherapy and autoimmune disease modelling within a single framework, it provides a preclinical rationale for dual endogenous TCR removal to improve specificity, safety, and therapeutic efficacy in TCR-based cell therapies.
Giorgia Zanetti, Sameena Nikhat, Mateusz Legut, Austin Chen, Farshid Fathi, Nathan Suek, Nato Teteloshvili, Hao Wei Li, Xiaolan Ding, Daniel Traum, Klaus H. Kaestner, Ryan E. Hoang, Andrew K. Sewell, Audrey V. Parent, Remi J. Creusot, Megan Sykes, Mohsen Khosravi-Maharlooei